Integrated genetic and pharmacologic interrogation of rare cancers-Reference-Cited by-同舟云学术

Integrated genetic and pharmacologic interrogation of rare cancers

Published:2016-06-22 Issue:1 Volume:7 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Hong Andrew L.^ORCID,Tseng Yuen-Yi,Cowley Glenn S.,Jonas Oliver,Cheah Jaime H.,Kynnap Bryan D.,Doshi Mihir B.,Oh Coyin,Meyer Stephanie C.,Church Alanna J.,Gill Shubhroz,Bielski Craig M.,Keskula Paula,Imamovic Alma,Howell Sara,Kryukov Gregory V.,Clemons Paul A.,Tsherniak Aviad^ORCID,Vazquez Francisca,Crompton Brian D.,Shamji Alykhan F.,Rodriguez-Galindo Carlos,Janeway Katherine A.,Roberts Charles W. M.,Stegmaier Kimberly,van Hummelen Paul,Cima Michael J.,Langer Robert S.,Garraway Levi A.,Schreiber Stuart L.^ORCID,Root David E.,Hahn William C.,Boehm Jesse S.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/ncomms11987.pdf

Reference39 articles.

1. Basu, A. et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell 154, 1151–1161 (2013).

2. Domcke, S., Sinha, R., Levine, D. A., Sander, C. & Schultz, N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4, 2126 (2013).

3. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495–501 (2014).

4. Connor, E. & Cure, P. “Creating hope” and other incentives for drug development for children. Sci. Transl. Med. 3, 66cm1 (2011).

5. Yuan, H. et al. Use of reprogrammed cells to identify therapy for respiratory papillomatosis. N. Engl. J. Med. 367, 1220–1227 (2012).

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CDK4/6 inhibition augments anti-tumor efficacy of XPO1 inhibitor selinexor in natural killer/T-cell lymphoma;Cancer Letters;2024-08

2. The nuclear export protein exportin‐1 in solid malignant tumours: From biology to clinical trials;Clinical and Translational Medicine;2024-05

3. Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin;Communications Biology;2024-04-08

4. Tackling the Moving Mutant Target: Taxifolin Derivatives as Novel Putative E571K Exportin-1 Inhibitors for KRAS-mutant Lung Adenocarcinoma;2024 International Conference on Science, Engineering and Business for Driving Sustainable Development Goals (SEB4SDG);2024-04-02

5. A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancer;Cell Reports Medicine;2023-04